Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/128330
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Portell Buj, Elena | - |
dc.contributor.author | Vergara Gómez, Andrea | - |
dc.contributor.author | Alejo-Cancho, Izaskun | - |
dc.contributor.author | López Gavín, Alexandre | - |
dc.contributor.author | Monté, Maria Rosa | - |
dc.contributor.author | San Nicolás, Lorena | - |
dc.contributor.author | González Martín, Julián | - |
dc.contributor.author | Tudó i Vilanova, Griselda | - |
dc.date.accessioned | 2019-02-15T14:30:44Z | - |
dc.date.available | 2019-02-15T14:30:44Z | - |
dc.date.issued | 2019-02-01 | - |
dc.identifier.issn | 0022-2615 | - |
dc.identifier.uri | http://hdl.handle.net/2445/128330 | - |
dc.description.abstract | Tuberculosis (TB) remains a major threat to human health worldwide. The increasing incidence of non-tuberculous mycobacterial infections and particularly those produced by Mycobacterium avium has emphasized the need to develop new drugs. Additionally, high levels of natural drug resistance in non-tuberculous mycobacteria (NTM) and the emergence of multidrug-resistant (MDR) TB is of great concern. Antimicrobial peptides (AMPs) are antibiotics with broad-spectrum antimicrobial activity. The objective was to assess the activity of AMPs against Mycobacterium tuberculosis and M. avium clinical isolates. MICs were determined using microtitre plates and the resazurin assay. Mastoparan and melittin showed the greatest activity against M. tuberculosis, while indolicidin had the lowest MIC against M. avium. In conclusion, AMPs could be alternatives for the treatment of mycobacterial infections. Further investigation of AMPs' activity in combination and associated with conventional antibiotics and their loading into drug-delivery systems could lead to their use in clinical practice. | - |
dc.format.extent | 12 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Microbiology Society | - |
dc.relation.isformatof | Versió postprint del document publicat a: http://dx.doi.org/ 10.1099/jmm.0.000912 | - |
dc.relation.ispartof | Journal of Medical Microbiology, 2019, vol. 68, num. 2 | - |
dc.relation.uri | http://dx.doi.org/ 10.1099/jmm.0.000912 | - |
dc.rights | (c) Portell Buj et al., 2019 | - |
dc.source | Articles publicats en revistes (Fonaments Clínics) | - |
dc.subject.classification | Tuberculosi | - |
dc.subject.classification | Malalties per micobacteris | - |
dc.subject.other | Tuberculosis | - |
dc.subject.other | Mycobacterial diseases | - |
dc.title | In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2019-02-14T15:28:19Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (ISGlobal) Articles publicats en revistes (Fonaments Clínics) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Portell-BujE_J_Med_Microbiol_Postprint_2019.pdf | 215.39 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.